The MeCo Score™ is the first and only clinically validated prognostic and predictive biomarker to help improve therapy selection for patients with early-stage breast cancer who may benefit from an FDA-approved antifibrotic therapy (1,2,3).
In effect, our technology unlocks a fundamentally new way to treat breast cancer.
Our landmark Phase 2 clinical study demonstrated that patients with High MeCo Score breast tumors who received antifibrotic therapy experienced a remarkable benefit: 62% reduced risk of recurrence over 9.7 years on average (p=0.031) (3,4).
This stunning improvement in the magnitude + duration of long-term survival rate appears to be unprecedented among all targeted therapies ever trialed for breast cancer using a chemotherapy or endocrine therapy backbone (4).
Partnerships & Collaborations
Funding
Affiliations
References
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
[3] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. Nov 15;30(22):5094-5104. doi: 10.1158/1078-0432.CCR-24-1518
[4] Event-free survival (EFS) after antifibrotic therapy (nintedanib) + chemotherapy vs. chemotherapy alone.
Notes: The prescribing information for the FDA-approved therapy listed in the MeCo Score test report may not include the associated biomarker. The proposed intended use for the MeCo Score test and its cut-off value for biomarker-positivity are subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the US Food and Drug Administration.
Copyright © 2025 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.